ReviewJournal of clinical medicine2022
COVID-19, Vaccines, and Thrombotic Events: A Narrative Review.
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Macular and retinal manifestations following COVID-19 vaccinations: a 2025 update systematic review and meta-analysis.Eye (London, England) · 2026Pooled it
- Protective immunity in hamsters from an oral Nipah vaccine correlates with pseudovirus neutralising antibody titre.Scientific reports · 2026Article
- Novel adenovirus vaccine vectors lacking thrombosis-associated interactions with platelet factor 4.iScience · 2026Article
- Antiviral Inactivated Vaccines: Looking to the Past to Face the Future-A Narrative Review.Vaccines · 2025Review
- Myocardial Necrosis in a Child After COVID-19: A Case Report.Clinical case reports · 2025Article
- The early impact of COVID-19 vaccines on major events in cardiac, pulmonary, and thromboembolic disease: a population-based study.The Korean journal of internal medicine · 2025Article
- Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2.Vaccines · 2025Review
- [Platform technologies in vaccine development].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2025Review
- Influence of the Covid-19 pandemic on cerebrovascular diseases in the Sao Paulo region of Brazil.Communications medicine · 2025Article
- Role of homologous recombination/recombineering on human adenovirus genome engineering: Not the only but the most competent solution.Engineering microbiology · 2024Review
- Anti-infection effects of heparin on SARS-CoV-2 in a diabetic mouse model.Zoological research · 2023Article
- Blood Coagulation and Thrombotic Disorders following SARS-CoV-2 Infection and COVID-19 Vaccination.Biomedicines · 2023Review
- The Year 2022 in Cardiovascular Diseases-Clinics and practice · 2023Article
- Cerebellar and brainstem stroke possibly associated with booster dose of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine.BMJ case reports · 2023Article
- Approach to the Patient With Adrenal Hemorrhage.The Journal of clinical endocrinology and metabolism · 2023Article
- Health and Well-Being through COVID-19 Vaccination: Physical, Oral, and Psychological Effects.International journal of environmental research and public health · 2023Article
- The Adenovirus Vector Platform: Novel Insights into Rational Vector Design and Lessons Learned from the COVID-19 Vaccine.Viruses · 2023Review
- Retinal Changes After COVID-19 Infection and COVID-19 Vaccination.International medical case reports journal · 2023Article
- Vaccine Side Effects in Health Care Workers after Vaccination against SARS-CoV-2: Data from TüSeRe:exact Study.Viruses · 2022Article
- Molecular Mechanisms of Pathogenesis, Prevention, and Therapy of COVID-19: Summarizing the Results of 2021.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease 2019 (COVID-19), a deadly pandemic that has affected millions of people worldwide, is associated with cardiovascular complications, including venous and arterial thromboembolic events. Viral spike proteins, in fact, may promote the release of prothrombotic and inflammatory mediators. Vaccines, coding for the spike protein, are the primary means for preventing COVID-19. However, some unexpected thrombotic events at unusual sites, most frequently located in the cerebral venous sinus but also splanchnic, with associated thrombocytopenia, have emerged in subjects who received adenovirus-based vaccines, especially in fertile women. This clinical entity was soon recognized as a new syndrome, named vaccine-induced immune thrombotic thrombocytopenia, probably caused by cross-reacting anti-platelet factor-4 antibodies activating platelets. For this reason, the regulatory agencies of various countries restricted the use of adenovirus-based vaccines to some age groups. The prevailing opinion of most experts, however, is that the risk of developing COVID-19, including thrombotic complications, clearly outweighs this potential risk. This point-of-view aims at providing a narrative review of epidemiological issues, clinical data, and pathogenetic hypotheses of thrombosis linked to both COVID-19 and its vaccines, helping medical practitioners to offer up-to-date and evidence-based counseling to their often-alarmed patients with acute or chronic cardiovascular thrombotic events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.